Subscribe

OdontoPrev S.A. (ODPV3.SA)

BRL15.34 +0.09 (+0.59%)
BR SAO Healthcare Medical - Healthcare Plans
Address Alameda Araguaia, 2104 06455-000
Barueri, SP, BR
CEO Elsen Christian de Carvalho Carmo
Website odontoprev.com.br
IPO 2006-12-01
ISIN BRSAUDACNOR9

Explore sections of this company profile

Description

Odontoprev S.A. provides private dental care plans in Brazil. The company operates through Corporate, Small and Medium-Sized Enterprise (SME), Individual, and Other segments. The company manages and sells dental care plans to corporations and/or individuals. It is also involved in commercial advisory, consulting, and business management services; develops and licenses software programs; wholesale and retail trade of products and equipment, sanitizers, drugs, medicines, pharmaceutical inputs, and related items; provision of storage, loading, organization, tidying, custody of goods, technical, and administrative programming services, as well as general management of assets and business. In addition, the company engages in integrating technologies to develop dental solutions; and provide specialized services related to accidents and illnesses, besides actuarial, financial, administrative, and commercial and risk management services. Odontoprev S.A. was founded in 1987 and is headquartered in Barueri, Brazil. Odontoprev S.A. is a subsidiary of Bradesco Saúde S.A.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
BRL15.34 +0.09 (+0.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.52
Float Shares
252.88M
Free Float %
46.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-5.34% -9.11% -7.24% +20.17% +18.58% +28.21% +31.26% +48.50% +53.09% +98.34% +3,200.77%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
15.34
DCF (Unlevered) 30.52 +99.0%
DCF (Levered) 35.69 +132.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 44% Bullish
Rating 2026-05 Change
Strong Buy 2 +1
Buy 2 0
Hold 4 -2
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
9.63
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
9 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers ★ Strong MOAT
  • ✓
    Revenue growth Medical - Healthcare Plans: +11.8%
    +6.1% Q1'26: +4.6% (vs Q1'25)
  • ✓
    EPS growth Medical - Healthcare Plans: -1.4%
    +8.1% ★ Q1'26: -9.7% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Healthcare Plans: +15.1%
    +20.9% Q1'26: -0.1% (vs Q1'25)
  • ✓
    EBIT margin Medical - Healthcare Plans: +3.3%
    +29.8% ★ Q1'26: +32.1% (vs Q1'25)
  • ✓
    ROIC Medical - Healthcare Plans: +6.7%
    +49.4% ★ Q1'26: +58.4% (vs Q1'25)
  • ✓
    Share dilution Medical - Healthcare Plans: +2.1%
    -0.3% Q1'26: -0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Plans: 0.93×
    0.04× ★ Q1'26: 0.02× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.60) × ERP
WACC = 100% × Ke + 0% × Kd (157.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 30.52 Current price: 15.34
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
6 Rev. Ana.
3 EPS Ana. 		Dec 2027
8 Rev. Ana.
5 EPS Ana. 		Dec 2028
4 Rev. Ana.
3 EPS Ana. 		Dec 2029
3 Rev. Ana.
1 EPS Ana.
Revenue
1.25B
est: 1.24B (+0.4%)
1.37B
est: 1.36B (+0.2%)
1.44B
est: 1.44B (-0.1%)
1.59B
est: 1.59B (+0.3%)
1.81B
est: 1.82B (-0.7%)
1.77B
est: 1.76B (+0.3%)
1.85B
est: 1.85B (-0.4%)
1.85B
est: 1.94B (-4.4%)
2.12B
est: 2.38B (-10.8%)
2.28B
est: 2.26B (+1.1%)
2.42B
est: 2.42B (+0.0%)
2.54B
2.51B – 2.56B
+5.0% YoY
2.71B
2.65B – 2.80B
+6.7% YoY
2.91B
2.91B – 2.92B
+7.4% YoY
3.19B
3.13B – 3.25B
+9.4% YoY
EBITDA
340.57M
est: 453.96M (-25.0%)
311.59M
est: 496.98M (-37.3%)
754.38M
est: 524.88M (+43.7%)
422.79M
est: 578.89M (-27.0%)
434.27M
est: 664.41M (-34.6%)
553.87M
est: 642.14M (-13.7%)
614.40M
est: 676.30M (-9.2%)
590.63M
est: 707.87M (-16.6%)
1.02B
est: 871.57M (+17.4%)
858.30M
est: 827.49M (+3.7%)
784.43M
est: 887.68M (-11.6%)
931.67M
919.94M – 940.53M
+5.0% YoY
994.42M
971.42M – 1.03B
+6.7% YoY
1.07B
1.07B – 1.07B
+7.4% YoY
1.17B
1.15B – 1.19B
+9.4% YoY
EBIT
312.12M
est: 399.29M (-21.8%)
280.41M
est: 437.13M (-35.9%)
573.46M
est: 461.67M (+24.2%)
407.04M
est: 509.18M (-20.1%)
408.85M
est: 584.39M (-30.0%)
523.91M
est: 564.81M (-7.2%)
550.16M
est: 594.85M (-7.5%)
553.61M
est: 622.62M (-11.1%)
760.79M
est: 762.86M (-0.3%)
802.15M
est: 724.28M (+10.8%)
721.27M
est: 776.96M (-7.2%)
815.47M
805.20M – 823.22M
+5.0% YoY
870.39M
850.26M – 899.16M
+6.7% YoY
935.05M
933.38M – 936.71M
+7.4% YoY
1.02B
1.00B – 1.04B
+9.4% YoY
Net Income
220.95M
est: 201.85M (+9.5%)
215.99M
est: 202.16M (+6.8%)
502.92M
est: 405.59M (+24.0%)
284.79M
est: 265.71M (+7.2%)
284.76M
est: 280.35M (+1.6%)
361.13M
est: 335.38M (+7.7%)
380.36M
est: 344.45M (+10.4%)
365.86M
est: 453.20M (-19.3%)
511.39M
est: 525.68M (-2.7%)
539.24M
est: 535.53M (+0.7%)
582.57M
est: 582.57M (+0.0%)
593.55M
590.30M – 596.79M
+1.9% YoY
617.16M
564.46M – 688.10M
+4.0% YoY
737.59M
679.10M – 796.09M
+19.5% YoY
1.05B
1.03B – 1.08B
+42.7% YoY
SGA
136.93M
est: 100.41M (+36.4%)
141.02M
est: 109.92M (+28.3%)
178.04M
est: 116.09M (+53.4%)
235.89M
est: 128.04M (+84.2%)
281.54M
est: 146.95M (+91.6%)
254.93M
est: 142.03M (+79.5%)
254.80M
est: 149.58M (+70.3%)
58.69M
est: 156.57M (-62.5%)
97.14M
est: 146.27M (-33.6%)
99.34M
est: 138.87M (-28.5%)
118.18M
est: 148.97M (-20.7%)
156.36M
154.39M – 157.84M
+5.0% YoY
166.89M
163.03M – 172.40M
+6.7% YoY
179.28M
178.96M – 179.60M
+7.4% YoY
196.10M
192.56M – 200.36M
+9.4% YoY
EPS
0.38
est: 0.37 (+2.9%)
0.37
est: 0.37 (+0.1%)
0.86
est: 0.74 (+15.9%)
0.49
est: 0.49 (+0.8%)
0.49
est: 0.51 (-4.4%)
0.62
est: 0.61 (+1.1%)
0.72
est: 0.63 (+14.3%)
0.66
est: 0.83 (-20.4%)
0.93
est: 0.95 (-2.4%)
0.99
est: 0.98 (+1.1%)
1.07
est: 1.04 (+2.9%)
1.09
1.08 – 1.09
+4.4% YoY
1.15
1.04 – 1.26
+6.0% YoY
1.33
1.25 – 1.46
+15.3% YoY
1.93
1.88 – 1.98
+45.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 A 4/5 5/5 5/5 5/5 3/5 3/5 2/5
2026-05-04 A+ 4/5 5/5 5/5 5/5 3/5 4/5 2/5
2026-04-30 A+ 4/5 5/5 5/5 5/5 3/5 4/5 2/5
2026-04-29 A+ 4/5 5/5 5/5 5/5 3/5 4/5 2/5
2026-04-28 A+ 4/5 5/5 5/5 5/5 3/5 4/5 2/5
2026-04-27 A 4/5 5/5 5/5 5/5 2/5 4/5 2/5
2026-04-24 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-23 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-22 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-20 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-17 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-16 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5
2026-04-15 A 4/5 5/5 5/5 5/5 2/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
520.45M
OE per share TTM
0.95
Owner's Yield
6.29%
Maintenance CapEx ratio
0.21%
Maint CapEx / Avg PPE
2.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
368.6K
Shares Outstanding
545.09M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
André Chidichimo de França Legal, Compliance Officer, DPO and Corporate Governance Officer & Director — male
Catarina Bruno IR & Treasury Supervisor — —
Elsen Christian de Carvalho Carmo Chief Executive Officer, Commercial Director & Director — male
José Roberto Borges Pacheco Investor Relations Officer, Chief Financial Officer & Director — male
Renato Alves Costa Velloso Dias Cardoso IT, Marketing, Sustainability Director & Board Director — male
Rose Gabay Human Resources Director & Director — female
Stella Hong IR Supervisor — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Healthcare Plans